8-K: Organon & Co. Reports Fourth Quarter and Full Year 2024 Results, Provides 2025 Guidance

Organon & Co. announced its fourth quarter and full year 2024 results, with full year revenue of $6.4 billion, up 2% as-reported and 3% at constant currency, and provided financial guidance for 2025.

Summary

• Organon reported full year 2024 revenue of $6.4 billion, a 2% increase as-reported and a 3% increase at constant currency.
• Diluted earnings per share (EPS) for 2024 were $3.33, while non-GAAP adjusted diluted EPS was $4.11.
• Adjusted EBITDA for 2024 was $1.96 billion, including $81 million of IPR&D, representing a 30.6% adjusted EBITDA margin.
• For the fourth quarter of 2024, total revenue was $1.592 billion, flat year-over-year.
• Women's Health revenue was flat in Q4 2024, with Nexplanon growth offsetting a decline in NuvaRing.
• Biosimilars revenue decreased by 18% in Q4 2024 due to the timing of tenders in Brazil and competitive pricing pressure.
• Established Brands revenue grew by 2% in Q4 2024, driven by Emgality and Vtama.
• Net income for 2024 was $864 million, or $3.33 per diluted share, compared to $1,023 million, or $3.99 per diluted share in 2023.
• The company's 2025 financial guidance includes revenue between $6.125 billion and $6.325 billion, with an approximate $200 million negative impact from foreign exchange.
• The adjusted EBITDA margin is expected to be between 31.0% and 32.0% for 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While the company faces challenges like LOE and FX headwinds, it has shown resilience in revenue growth and EBITDA margin management. The focus on strategic growth drivers and pipeline development is also encouraging.

Positives

• Organon achieved its third year of constant currency revenue growth in 2024.
• The company delivered adjusted EBITDA margin expansion ex-IPR&D in 2024.
• Nexplanon achieved record revenue of $963 million, with growth of 17% ex-FX.
• Biosimilars revenue increased by 12% due to the growth of Hadlima.
• The company is focused on disciplined operating costs to support adjusted EBITDA margins.
• Emgality and Vtama contributions offset the impact of Atozet's loss of exclusivity.

Negatives

• NuvaRing revenue declined due to generic competition.
• Biosimilars revenue declined in Q4 2024 due to the timing of tenders and competitive pricing pressure.
• The company faces a loss of exclusivity for Atozet in certain markets.
• The company anticipates a $200 million negative impact from foreign exchange in 2025.
• Gross margin was negatively impacted by higher year-over-year amortization related to acquisitions and acquisition-related expenses.

Risks

• The company faces risks related to clinical trial and regulatory approvals.
• There is a risk of an inability to adapt to the industry-wide trend toward highly discounted channels.
• Difficulties in implementing or executing on Organon's acquisition strategy could impact results.
• Changes in tax laws or other tax guidance could adversely affect the company's financial results.
• Expanded brand and class competition in the markets in which the company operates poses a risk.
• Global tensions may result in disruptions in the broader global economic environment.
• Pricing pressures globally, including rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and health care reform, pharmaceutical reimbursement and pricing in general.

Future Outlook

Organon anticipates full year 2025 revenue between $6.125 billion and $6.325 billion, with an adjusted EBITDA margin between 31.0% and 32.0%.

Management Comments

• In 2024 we achieved our third year of constant currency revenue growth and delivered Adjusted EBITDA margin expansion ex-IPR&D, said Kevin Ali, Organon's chief executive officer.
• Our 2025 financial guidance reflects the potential for a fourth year of constant currency revenue growth despite the loss of exclusivity (LOE) of our second largest product, Atozet, in certain markets.
• Further, we will continue to be extremely disciplined on operating costs to support Adjusted EBITDA margins ex-IPR&D of 31.0% or better.

Industry Context

Organon's focus on women's health, biosimilars, and established brands aligns with the growing demand in these sectors. The company's strategic roadmap emphasizes growth in key products like Nexplanon and Vtama, which are positioned to compete in their respective markets.

Comparison to Industry Standards

• Organon's Adjusted EBITDA margin of 30.6% is comparable to other large pharmaceutical companies, but it is important to consider the specific product mix and market conditions.
• For example, Teva Pharmaceutical Industries, a major player in generics and biosimilars, has reported adjusted EBITDA margins in a similar range.
• Companies like Viatris, which also focus on established brands and biosimilars, are relevant comparators.
• Organon's growth in Nexplanon is notable, as it aims to reach blockbuster status, competing with other long-acting reversible contraceptives (LARCs) in the women's health market.
• The successful launch of Vtama positions Organon to compete with established players in the dermatology space, such as LEO Pharma and Galderma.

Stakeholder Impact

• Shareholders will receive a quarterly dividend of $0.28 per share.
• Employees are part of a company that is focused on growth and strategic development.
• Customers will benefit from the company's focus on women's health and innovative solutions.
• Suppliers and creditors are part of a stable and growing business.

Next Steps

• The company will continue to focus on strategic growth drivers such as Nexplanon, Vtama, and Emgality.
• Organon plans to maintain a deal cadence, managing net leverage to enhance its strategic therapeutic areas.
• The company will continue to build and progress its R&D pipeline.
• Organon will host a conference call at 8:30 a.m. Eastern Time today to discuss its fourth quarter and full year 2024 financial results.

Key Dates

Keywords

Organon, financial results, revenue, EBITDA, earnings, guidance, women's health, biosimilars, established brands, Nexplanon, Vtama, Emgality